These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32028755)

  • 1. Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate.
    Lee J; Yoo Y; Park S; Cho MS; Sung SH; Ro JY
    J Pathol Transl Med; 2020 Mar; 54(2):146-153. PubMed ID: 32028755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
    Chastain EC; Oliva IV; Osunkoya AO
    Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
    Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
    Fichtenbaum EJ; Marsh WL; Zynger DL
    Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
    Herawi M; Epstein JI
    Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
    Ali TZ; Epstein JI
    Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
    Huguet J
    Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dilemmas in the treatment of urothelial cancers of the prostate.
    Walsh DL; Chang SS
    Urol Oncol; 2009; 27(4):352-7. PubMed ID: 18439852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
    Wang W; Sun X; Epstein JI
    Am J Surg Pathol; 2008 Jun; 32(6):851-7. PubMed ID: 18408595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer.
    Patel SG; Cookson MS; Barocas DA; Clark PE; Smith JA; Chang SS
    BJU Int; 2009 Oct; 104(7):934-7. PubMed ID: 19338554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
    Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
    J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
    Mazzucchelli R; Barbisan F; Santinelli A; Scarpelli M; Galosi AB; Lopez-Beltran A; Cheng L; Kirkali Z; Montironi R
    Urology; 2009 Aug; 74(2):385-90. PubMed ID: 19501882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
    Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
    Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Osunkoya AO; Epstein JI
    Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance.
    Shen SS; Lerner SP; Muezzinoglu B; Truong LD; Amiel G; Wheeler TM
    Hum Pathol; 2006 Jun; 37(6):726-34. PubMed ID: 16733214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy.
    Oliai BR; Kahane H; Epstein JI
    Am J Surg Pathol; 2001 Jun; 25(6):794-801. PubMed ID: 11395558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
    Hameed O; Sublett J; Humphrey PA
    Am J Surg Pathol; 2005 May; 29(5):579-87. PubMed ID: 15832080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome?
    Oliva IV; Smith SL; Chen Z; Osunkoya AO
    Hum Pathol; 2011 Jan; 42(1):51-6. PubMed ID: 20870265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.